Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study.

Journal: BMC medicine
Published Date:

Abstract

BACKGROUND: The introduction of multiparameter MRI and novel biomarkers has greatly improved the prediction of clinically significant prostate cancer (csPCa). However, decision-making regarding prostate biopsy and prebiopsy examinations is still difficult. We aimed to establish a quick and economic tool to improve the detection of csPCa based on routinely performed clinical examinations through an automated machine learning platform (AutoML).

Authors

  • Huiyong Zhang
    Key Laboratory of Noise and Vibration Research, Institute of Acoustics, Chinese Academy of Sciences, Beijing, China.
  • Jin Ji
    Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.
  • Zhe Liu
    Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, Republic of Korea.
  • Huiru Lu
    Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
  • Chong Qian
    Department of Urology, The First People's Hospital of Yulin, Yulin, 537000, Guangxi, China.
  • Chunmeng Wei
    Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China.
  • Shaohua Chen
    Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China.
  • Wenhao Lu
    School of Electrical and Electronic Engineering, Nanyang Technological University, Nanyang Avenue, 639798, Singapore.
  • Chengbang Wang
    Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China.
  • Huan Xu
    School of Food Science and Engineering, Hainan University 58 Renmin Avenue Haikou 570228 China zhangzeling@hainanu.edu.cn benchao312@hainanu.edu.cn xuhuan.hnu@foxmail.com qichen@hainanu.edu.cn sunzhichang11@163.com hmcao@hainanu.edu.cn.
  • Yalong Xu
    Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.
  • Xi Chen
    Department of Critical care medicine, Shenzhen Hospital, Southern Medical University, Guangdong, Shenzhen, China.
  • Xing He
    University of Florida, Gainesville, Florida, USA.
  • Zuheng Wang
    Department of Urology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, China.
  • Xiaodong Zhao
    Shandong Vocational Animal Science and Veterinary College, Weifang, China.
  • Wen Cheng
    Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
  • Xingfa Chen
    Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.
  • Guijian Pang
    Department of Urology, The First People's Hospital of Yulin, Yulin, 537000, Guangxi, China.
  • Guopeng Yu
    Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.
  • Yue Gu
    Key Laboratory of Computer Vision and System (Ministry of Education), School of Computer Science and Engineering, Tianjin University of Technology, Tianjin 300384, China. guyue@email.tjut.edu.cn.
  • Kangxian Jiang
    Department of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian, China.
  • Bin Xu
    Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Junyi Chen
  • Xuedong Wei
    Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Ming Chen
    Department of Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
  • Rui Chen
    College of Food Science and Engineering, Northwest A&F University, Yangling 712100, Shanxi, China.
  • Jiwen Cheng
    Department of Urology, Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China. chengjiwen1977@foxmail.com.
  • Fubo Wang
    Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, 530021, Guangxi, China. wangbofengye@163.com.